Trump's physician said the president underwent cardiac and abdominal imaging. The White House released the results of President Donald Trump's recent advanced imaging tests on Monday, describing them ...

Seven days ago, Gophers men's basketball was rated 64th in the country according to KenPom.com, and it had games against Missouri and Green Bay on the schedule. After a blowout loss and a hard-fought ...

CERRITOS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, ...

What if the key to unlocking the full potential of AI isn’t in the technology itself, but in the way you communicate with it? Imagine spending hours refining a prompt for an AI system, only to receive ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/solstice-advanced-materials-reports-third-quarter-2025-results-302606539.html ...

Election Day is here in Virginia. At stake Tuesday is control of the top three statewide offices of governor, lieutenant governor and attorney general; the General Assembly’s House of Delegates; and ...

Former Gov. Jim McGreevey of New Jersey left office in 2004 amid a sex scandal. He is seeking political rebirth as mayor of Jersey City in a field of locally prominent candidates. If no one receives ...

Use $3 billion from the state’s general fund to establish the Dementia Prevention and Research Institute of Texas. race called Source: Election results and race calls are from The Associated Press. By ...

CFA Institute, the global association of investment professionals, announces that of the 14,538 candidates worldwide who sat for the Level III CFA® Program exam in August 2025, 50 percent have passed.

A new drug combination to treat advanced recurring prostate cancer has shown remarkable results in a long-term trial, lowering the risk of death after eight years by 40.3%. What's more, the drug ...

VT3989 is a first-in-class YAP-TEAD inhibitor from Vivace Therapeutics that is currently in Phase I/II trials for patients with advanced solid tumors, with a focus on refractory mesothelioma In this ...